Active	Status	Sponsor type	Region	Phase	Filter
13 Active 5 Inactive 18 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Martelli, Maurizio
DREAMM8, NCT04484623 / 2018-004354-21: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma Jan 2024 - Dec 2024: Market entry for 2L multiple myeloma (based on DREAMM-7 trial) Oct 2024 - Dec 2024 : Acceptance of regulatory submission in US for 2L+ multiple myeloma Jul 2024 - Dec 2024 : Acceptance of regulatory submission in EU for 2L+ multiple myeloma (based on DREAMM-8 trial) Jan 2024 - Dec 2024: Regulatory approval in US for 2L+ multiple myeloma (based on DREAMM-7 trial) Jan 2024 - Dec 2024: Regulatory approval in EU for 2L+ multiple myeloma (based on DREAMM-7 trial) Jul 2024 - Dec 2024 : Acceptance of regulatory submission in Japan for 2L+ multiple myeloma (based on DREAMM-8 trial) Jul 2023 - Dec 2023: Data readout from DREAMM-8 trial in combination with pomalidomide and dexamethasone for 2L+ multiple myeloma Jul 2023 - Dec 2023: Acceptance of regulatory submission in US for 2L+ multiple myeloma (based on DREAMM-8 trial) Jul 2023 - Dec 2023: Acceptance of regulatory submission in EU for 2L+ multiple myeloma (based on DREAMM-8 trial) Jul 2023 - Sep 2023 : Regulatory approval for 2L+ multiple myeloma (based on DREAMM-8 trial) Jul 2023 - Sep 2023 : Regulatory approval for 2L+ multiple myeloma (based on DREAMM-8 trial) Jan 2021 - Dec 2021 : Initiation of DREAMM-10 trial for 1L transplant ineligible multiple myeloma in combination with novel agent Dec 2020 - Dec 2020 : Data from DREAMM-8 trial for multiple myeloma at ASH 2020 More	Recruiting	3	357	Europe, Japan, US, RoW	Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib	GlaxoSmithKline	Multiple Myeloma	01/24	05/29
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance	Active, not recruiting	2	75	Europe	Ibrutinib, IMBRUVICA (commercial name)	Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.	DLBCL	07/24	07/27
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Recruiting	2	249	Europe, Canada, US, RoW	Pirtobrutinib	Loxo Oncology, Inc., Eli Lilly and Company	Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	06/28	12/28
DREAMM 9, NCT04091126 / 2019-003047-30: Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma From DREAMM-9 trial for 1L transplant ineligible multiple myeloma at ASH 2021 Dec 2021 - Dec 2021: From DREAMM-9 trial for 1L transplant ineligible multiple myeloma at ASH 2021	Recruiting	1	144	Europe, Canada, US, RoW	Belantamab mafodotin, Bortezomib, Lenalidomide, Dexamethasone	GlaxoSmithKline	Multiple Myeloma	11/24	06/25